12 – 14/02/2026

THE MET, Thessaloniki.

IASIS PHARMA participated at the “Panhellenic Seminars of the Cardiology Working Groups”, held in Thessaloniki, at the Met Hotel, from February 12 to 14, 2026.

In IASIS PHARMA exhibition stand, the following products were presented:

  • RosuZet®: New Product Launching. Fixed-dose combination of Rosuvastatin & Ezetimibe, in a single dosage form, in packages of 30 f.c. tabs available in the full spectrum of strengths: (Rosuvastatin / Ezetimibe)

5 / 10mg,
10 / 10mg,
20 / 10mg,
40 / 10mg.

  • Rami–Amlo®: an original fixed-dose combination of Ramipril & Amlodipine in a single dosage form, in packages of 28 capsules, available in 4 strengths:
    5mg/5mg,
    5mg/10mg,
    10mg/5mg,
    10mg/10mg.
  • Rami–Amlo plus®: also an original fixed-dose combination of Ramipril – Amlodipine –Hydrochlorothiazide, which is available in packages of 30 capsules, in a wide range of strengths:
    (Ramipril / Amlodipine / Hydrochlorothiazide)
    5 mg/5 mg/12,5 mg,
    5 mg/5 mg/25 mg,
    10 mg/5 mg/25 mg,
    10 mg/10 mg/25 mg
  • MAG-IASIS®: the first uniquely effective combination of 1193.57 mg Magnesium citrate & 667.56 mg Magnesium aspartate, equivalent to 243 mg Magnesium, indicated for magnesium deficiency, in the form of 40 effervescent tablets.
  • Licepler®: (Eplerenone) available in packages of 30 film-coated tablets, in 25mg and 50mg strengths.

 

omades-ergasias-2026-copy